Cargando…
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures
Background/Aim: Pancreatic adenocarcinoma is a highly malignant tumor. Synergistic combinations of anticancer agents for the effective treatment of pancreatic cancer patients are urgently needed. Here, we investigated the combined effect of celecoxib (CEL) and salirasib (SAL) on pancreatic cancer ce...
Autores principales: | Li, Dongli, Ma, Yuran, Liu, Wenfeng, Ren, Xiang, Chen, Min, Xu, Xuetao, Sheng, Zhaojun, Zhang, Kun, Zhou, Renping, Goodin, Susan, Zheng, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378654/ https://www.ncbi.nlm.nih.gov/pubmed/32714082 http://dx.doi.org/10.7150/ijms.47546 |
Ejemplares similares
-
Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells via down regulation of NF-κB, STAT3, and ERK activation
por: Ma, Yuran, et al.
Publicado: (2020) -
Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells
por: Wang, Xiao, et al.
Publicado: (2022) -
Expression profile of Oct-4 lung cancer-specific marker prior and subsequent to a salirasib treatment regime
por: Ao, Xiang, et al.
Publicado: (2017) -
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors
por: DING, NING, et al.
Publicado: (2014) -
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms
por: Charette, N, et al.
Publicado: (2013)